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Nitric oxide (NO) is a promising pharmaceutical agent that has vasodilative, antibacterial, and tumoricidal eﬀects. To study
the complex and wide-ranging roles of NO and to facilitate its therapeutic use, a great number of synthetic compounds (e.g.,
nitrosothiols, nitrosohydroxyamines, N-diazeniumdiolates, and nitrosyl metal complexes) have been developed to chemically
stabilize and release NO in a controlled manner. Although NO is currently being exploited in many biomedical applications, its
use is limited by several factors, including a short half-life, instability during storage, and potential toxicity. Additionally, eﬃcient
methods of both localized and systemic in vivo delivery and dose control are needed. One strategy for addressing these limitations
and thus increasing the utility of NO donors is based on nanotechnology.
1.Introduction
1.1.DiverseNOFunctions. Nitricoxide(NO)isafree-radical
gas and one of the smallest endogenous molecules with the
ability to function as a chemical messenger, particularly in
cells of the vascular endothelium and immune and neural
systems. NO plays a critical role in regulating a diverse range
of physiological processes, including cellular diﬀerentiation
and apoptosis [1–10].
Medical and scientiﬁc interest in NO has grown expo-
nentially since 1992, when it was nominated “Molecule of
the Year.” Its documented physiological impacts are ever-
expanding [11]. Until 1987, NO was known solely as a
dangerous atmospheric pollutant generated by industrial
processes and automotive engines and as a potential carcino-
gen [12, 13]. However, by the end of 1987, the discovery of
NO synthesis in mammalian cells revealed that this molecule
exerts physiological eﬀects, many of which still have not
been completely characterized [8, 13]. This discovery led to
a rapid increase in research focused on NO [14–22]. NO
is now known as one of the most important mediators of
intra- and extracellular processes and is a major target of the
pharmaceutical industry [12].
Endogenous NO is produced enzymatically by three
distinct nitric oxide synthases via L-arginine conversion. The
NO generated by each enzyme diﬀers considerably in its
pattern of expression and regulation, likely reﬂecting site-
speciﬁc functions [13, 23]. These functions result in both
beneﬁcial and detrimental outcomes [12]. Regarding the
former, NO may help to improve the prognosis of diﬀerent
human pathologies, including cardiovascular, hematolog-
ical, metabolic, gastrointestinal, respiratory, neurological,
renal, genitourinary, musculoskeletal/connective tissue, and
obstetric/gynecological diseases as well as cancer [13]. Some
of the speciﬁc functions of NO are as follows.
(i) Maintenance of Vascular Tone and Blood Pressure:
Vascular tone is usually maintained by a steady
release of tiny amounts of NO from the vascular
endothelium. This NO release is triggered by friction
exerted by circulating cells (shear stress) and results
in slight vasodilatation [13, 24]. Blood pressure and
pulsate ﬂow also regulate the release of NO under
physiological conditions, with NO inhibition leading
to a drastic increase in blood pressure [12, 25].
(ii) Regulation of Immunity and Inﬂammation: NO is an
important cytotoxic mediator of activated immune
cells capable of killing pathogenic agents, such as
bacteria, parasites, and viruses, as well as tumor
cells. NO can also inhibit the inﬂammation of blood
vessels by blocking exocytosis of various mediators
from endothelial cells, macrophages, and cytotoxic T
lymphocytes [12, 13].2 Journal of Drug Delivery
(iii) Inhibition of Monocyte and Neutrophil Adhesion to
the Vascular Endothelium: NO donors have shown
to be potent inhibitors of neutrophil and monocyte
adhesiontothevascularendothelium,acomplicating
factor in the pathogenesis of atherosclerosis [12, 26].
(iv) Antiproliferative Eﬀects: Cellular proliferation in the
muscular layer of the blood vessel has a key role
in narrowing the vascular lumen. NO produced by
the vascular endothelium or arising from exogenous
donors can inhibit this proliferation although the
mechanism underlying its antiproliferative activity is
not well understood [12, 27, 28].
(v) Antioxidative Eﬀects: Oxidative stress contributes to
thromboembolicdisease.NOinducestheproduction
of the enzyme superoxide dismutase in the muscular
layer of the blood vessels and in the extracellular
space, decreasing the O2– available and the produc-
tion of ONOO– [12, 29].
(vi) Regulation of Neurotransmission: NO regulates the
activity of certain motor neurons in the parasympa-
thetic branch of the autonomic nervous system [13].
(vii) Regulation of Platelet Function: NO mediates the
adhesion and aggregation of platelets [13].
(viii) Direct and Indirect Stimulation of Endocrine and
Exocrine Secretion: NO regulates the release of
gonadotropin-releasing hormone (GSH) from the
hypothalamus and adrenaline from the adrenal
medulla as well as exocrine secretions (e.g., amylase
from the pancreas) [13].
(ix) Regulation of Kidney Function: Release of NO at the
level of the glomerulus increases blood ﬂow and the
rate of ﬁltration, and urine formation [13].
(x) Regulation of Reproductive Function: NO can
improve penile erection, fertilization and uterine
relaxation during pregnancy [13].
(xi) Role As a Messenger/Modulator: NO functions in a
variety of essential biological processes [12].
Meanwhile, in addition to its beneﬁcial eﬀects, NO
is a potentially toxic agent. This toxicity is particularly
apparent during oxidative stress; when NO generates, O2
intermediates and leads to antioxidant deﬁciency [12].
1.2. NO Donors and Potential Therapeutics. Research on
the biological functions of NO and other reactive nitrogen
speciesrequiresexogenoussourcesofNOdonors,whichmay
serveasbothresearchtoolsanddrugs.Sincemid-1980,newly
developed NO donors have oﬀered several advantages over
older donors, such as spontaneous NO release or controlled
release targeting certain tissues. The synthesis of molecules
capable of releasing optimal amounts of NO at the right time
and the right place poses a great challenge to pharmaceutical
research. Several known drugs have demonstrated partial or
total modulation of NO metabolism with diverse therapeutic
results.Classicorganicnitratesparticularlyshowedbeneﬁcial
therapeutic eﬀects, yet they can induce such undesirable
eﬀects as tolerability, abrupt cephalea, and hypotension [13].
The classiﬁcation of NO donors can be confusing,
because all have the potential to be oxidized or reduced,
producing reactive nitrogen species. However, similar chem-
ical structures often have similar mechanisms of NO release.
Most NO donors are low-molecular-weight compounds,
including nitrates, nitrites, N-nitroso, C-nitroso, certain
heterocycles, metal-NO complexes, and diazeniumdiolates
[30].Dependingonthechemicalnatureofthesecompounds,
NO is released spontaneously either in the presence or the
absence of a catalyst [8].
Diﬀerent classes of NO donors have been applied
to studying biological systems. Seabra and Dur´ an [31]
described the use of disodium 1-[(2-carboxylato)pyr-
rolidin-1-yl]diazen-1-ium-1,2-diolate (PROLI/NO), 1-
[N-(3-ammoniopropyl)-N-(n-propyl)amino]-diazen-1-
ium-1,2-diolate (PAPA/NO), 1-[N-(3-aminopropyl)-N-
(3-ammoniopropyl)diazen-1-ium-1,2-diolate (DPTA/NO)
[32], 1-[N-(2-aminoethyl)-N-(2-ammonioethyl)amino] di-
azen-1-ium-1,2-diolate (DETA/NO) [33], S-nitrosogluta-
thione (GSNO) and S-nitroso-N-acetylcysteine (SNAC)
[34–37], ruthenium derivatives [22, 38–40], and N-
nitrosomelatonin (NOMela) [34]. However, according
to Scatena et al. [13], while there are many new NO-
releasing molecules, there are few real NO-releasing
drugs. Among the molecules that are pharmacologically
eﬀective as NO-releasing drugs are organic nitrates (glycerol
trinitrate, isosorbide dinitrate, isosorbide mononitrate,
pentaerythritol tetranitrate, LA-419, piperazine derivative
nitrates, and benzyl derivative nitrates), S-nitrosothiols
(S-nitroso-N-acetyl-penicillamine, S-nitroso-glutathione, S-
nitroso-N-valeryl-penicillamine, and S-nitroso-glucopyra-
nose), diazeniumdi-olates-NONOates (JS-K, CB-3-100,
PABA/NO derivatives, and NONOate hybrid drugs (NONO-
NSAIDs)), furoxans (CHF 2206, furoxans hybrid drugs),
zeolites (mesoionic oxatriazoles (MOTA)), NO hybrid
drugs (NO-hydrocortisone, NO-enalapril, and NO-
ursodeoxycholic) and hydroxyurea.
NOdonorscanbeincorporatedintoorchemicallylinked
to biopolymers, mimicking endogenous NO production at a
targetsite[31,41].Currently,themostcriticalobstacletothe
development of new NO donor drugs is release at a speciﬁc
tissue site at an optimal concentration, with the purpose of
achieving a therapeutic eﬀect and minimizing toxic eﬀects
[13].
1.3. NO and Nanotechnology. Although NO is used in many
biomedical applications, its utility is limited by its short
half-life, instability during storage, and potential toxicity.
Eﬃcient methods of both localized and systemic in vivo
delivery and dose control are also lacking. Nanomaterials
are currently being harnessed to overcome these limitations.
These materials are usually able to load high amounts of
NO, are quite stable, are sometimes photoactive, and possess
demonstrable biological activity. Their surfaces can also
be chemically modiﬁed and optimized for speciﬁc medical
applications.Journal of Drug Delivery 3
There is particularly great interest in NO-releasing
blood-compatible polymeric materials for coating medical
devices, such as intravascular catheters, vascular grafts, coro-
naryarteryandvascularstents,andlong-termvascularaccess
devices. In these cardiovascular applications, continuous NO
release over days and even months is desired [31]. Due to the
crucial role of NO as an endogenous mediator of numerous
physiological processes in the cardiovascular, immune, and
nervous systems as well as in skin physiology, great eﬀort has
been devoted to the development of NO delivery systems for
therapeutic purposes over the last few years [42].
Drug-delivery technologies are being widely used by
pharmaceutical companies to expand the market for their
already established products [43]. Over the past two decades,
researchers have realized that nanotechnology is a funda-
mental part of drug development, resulting in the design
of a wide range of drug-delivery systems [44, 45]a n da
progressive increase in the number of commercially available
nanotechnology-based drugs [46–49]. Such novel delivery
systems may reduce drug side eﬀects,facilitate drug adminis-
tration,ensureorimprovepatientcompliance,decreasedrug
toxicity, enhance the bioavailability of drugs, and be tailored
toward speciﬁc therapeutic targets [6, 43].
Nanotechnology is a relatively new area and its applica-
tion in medicine is promising [45, 50, 51]. Nanoscale drug-
delivery systems may increase the duration of drug circula-
tion in the blood, allowing a reduction in the dose required
to achieve therapeutic levels over an extended period of time.
Nanomaterials may also deliver a drug directly to a target
site, reducing its toxicity, which contributes to a decrease
in side eﬀects [52–55]. At this target site, nanosystems
may accumulate at higher concentrations than conventional
drugs due to their small size, potententially increasing the
delivered drug’s therapeutic eﬃcacy [56]. Additionally, these
delivery systems can be employed to target very inaccessible
sites, such as the brain, if they are designed to permeate
biological barriers [57]. Finally, the formulation of a drug in
a nanoparticulate system can reduce renal and hepatic clear-
ance and decrease immune system recognition, optimizing
the drug’s pharmacokinetic properties and biodistribution
[58].
Nanocarriers not only improve drug solubility but also
drug stability, allowing further development of potentially
eﬀective compounds that were rejected during preclinical
or clinical research due to suboptimal pharmacokinetic or
biochemical properties. Thus, nanocarriers may facilitate the
development of multifunctional systems for targeted drug-
delivery [59, 60], combined therapies [56, 61], or systems
for simultaneous therapeutic and diagnostic applications.
Nanocarriersofnitricoxidemaketheagentmoreavailableto
the systemic circulation and also can enhance a target of NO,
the interaction of nitric oxide with blood vessels, through of
use of antibody moieties to selectively target drug-delivery
vehicles to blood vessels. In the remainder of this paper,
we will focus on the most clinically important NO-releasing
nanostructures.
2.Polymeric Nanocarriers
2.1. Polymeric Nanoparticles and Micelles. NO is frequently
administered via an NO donor, also known as a prodrug
because of the diﬃculty of delivering it directly. However,
most NO donors are labile, decomposing too rapidly to
be useful, while the lifetime of NO itself in tissues is a
mere 4–15seconds, corresponding to a diﬀusion distance of
approximately 150–500µm. The use of nanocarriers is one
viable alternative for improving the stability and therapeutic
delivery of NO [62, 63].
The use of polymeric nanoparticles and micelles as
nanocarriers for drug delivery has been extensively inves-
tigated. These systems can be used to increase the aque-
ous solubility of drugs and to modulate drug activity by
passive or active targeting to diﬀerent tissues. Further-
more, biodegradable polymers can degrade into nontoxic
monomers inside the body and are generally highly stable
in biological ﬂuids as well as during preparation and storage
[64–66]. Such biodegradable and biocompatible polymers
include polylactic acid (PLA), polyglycolic acid (PGA), and
polylactic-co-glycolicacid(PLGA).Thelatterisapprovedfor
therapeutic usebythe Food and DrugAdministration (FDA)
and is one of the most widely used polymers in nano- and
microparticle production [31, 67].
Polymericparticleswithadiameteroflessthan1µm[68]
(Figure 1) have shown advantages over liposomes in phys-
iochemical stability and encapsulation eﬃciency [69]. These
nanoparticles can be prepared by physiochemical, chemical
and mechanical methods [70]. However, drug release from
particles may vary according to the polymer used or the
drug encapsulated [71], while the method of encapsulation
and the experimental conditions may inﬂuence particle size,
morphology, and encapsulation eﬃciency [67].
Polymeric micelles are generally lower in size than
nanoparticles and liposomes and larger than dendrimers,
while suﬃciently small (less than 100nm in diameter) to
penetrate tissues. Additionally, liposomes can be eventually
dissembled after all drug has been delivered [63].
A small number of reports have been published on the
delivery of NO using polymeric systems. Oliveira et al. [6]
developed and characterized PLGA nanoparticles containing
the NO donor agent (trans-[RuCl([15]ane)(NO)]2+). One
year later, Jain et al. [71] demonstrated that stabilization
of NO pro-drugs and anticancer lead compounds via
their incorporation into polymer-protected nanoparticles
composed of polystyrene-b-PEG (PS-b-PEG) and PLA-b-
PEG may enhance their therapeutic eﬀects. Meanwhile,
Yoo et al. [72] described PLGA microparticles containing
an NO donor that eﬃciently delivered NO to the vaginal
mucosa, resulting in improved vaginal blood perfusion,
which may have implications in the treatment of female
sexual dysfunction. Another potential clinical application of
polymeric nanocarriers is in topical NO delivery, such as by
incorporation of NO donors into a liquid PEG/water matrix
[31]. Finally, Kanayama et al. [66] reported that PEGylated
polymermicellesmaybecapableofdeliveringexogenousNO
to tumor cells in a photocontrolled manner, resulting in an4 Journal of Drug Delivery
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Figure 1: Scanning electron micrograph of polymeric nanoparticles containing the NO donor agent trans-[RuCl([15]ane)(NO)]2+.( a )
Panoramic view. (b) Isolated magniﬁed particle. Reprinted from Oliveira et al. [6], with the permission of Editorial Executive, Research
Trends.
NO-mediated antitumor eﬀect, which indicates the promise
of this polymeric system in NO-based tumor therapy.
2.2. Dendrimers and Hydrogels. Dendrimers are monodis-
perse macromolecules with a tridimensional structure that is
highly ramiﬁcated and regular around the nucleus [64, 73].
The ability to store NO on a dendritic scaﬀold using the NO
donor N-diazeniumdiolate was ﬁrst demonstrated by Stasko
and Schoenﬁsch [74]. Benini et al. [75] then reported that
the system formed by anchoring of K[RuIII(edta)(Cl)] to
poly(amidoamine) dendrimers (PAMAM) can relax aortic
rings lacking endothelium and exert trypanocidal eﬀects.
Meanwhile, Stasko et al. [76] synthesized two generation-4
PAMAM dendrimers with S-nitrosothiol exteriors (Figure 2)
and characterized their ability to inhibit thrombin-mediated
platelet aggregation.
Another interesting delivery system is hydrogel (Figure
3), a three-dimensional hydrophilic polymeric network that
can absorb and retain a considerable amount of water while
maintaining shape. This system has enormous potential
in the design of closed-loop drug delivery. Due to their
highly hydrophilic characteristics, biodegradable hydrogels
have been widely used in biomedical applications, such as
drug and cell delivery [64, 77].
The gradual release of NO from a material arises from a
combination of the features of glassy matrices and hydrogels,
as reported by Friedman et al. [78]. These researchers
demonstrated that silane hydrogel containing NO pro-
motes a reduction in angiogenesis, preventing bacterial
dissemination from abscesses. Therefore, such materials may
potentially serve as topically applied antimicrobials for the
treatment of cutaneous infections and wounds [79, 80].
Additionally, NO-releasing hydrogel/glass hybrid nanopar-
ticles may be preferable to other NO-releasing compounds
because they do not depend on chemical decomposition, or
enzymatic catalysis but rather only on the rate of hydration
[23].
3.Lipid-BasedNanocarriers
3.1.Liposomes. Liposomesarevesiclesformedbyanaqueous
core surrounded by one or several phospholipid bilayers.
Hydrophilic drugs or active compounds can be incorporated
into the inner aqueous cavity, while lipophilic drugs may
be incorporated into the bilayer [81]. Liposomes are used
as nanovehicles in various clinical applications and are
potentially valuable vehicles for targeted therapeutics. One
beneﬁt of circulating liposomes is that they can accumulate
in tissues with high vascular permeability by simple passive
diﬀusion or extravasation, such as at the site of cancer,
inﬂammation, or ischemia. Liposomes can also be surface-
conjugated with molecules recognized by speciﬁc types of
cells or tissues for targeted delivery [82].
Liposomes also have applications in molecular imaging,
serving as a tool for diagnosis [83]. The encapsulation of
gases into liposomal formulations results in a contrast agent
that is suitable for ultrasound imaging. When this gas has a
therapeutic application, such as NO, the resultant echogenic
liposomes (ELIPs) can also be used for treatment of many
diseases [84]. Huang et al. [84] speciﬁcally developed a
bioactivegas-deliverymethod,usingELIPsastheNOcarrier,
to inhibit intimal hyperplasia. The release proﬁle of NO
from the NO-ELIP demonstrated an initial rapid burst
followed by a more sustained release. The delivery of NO to
VSMCs using the NO-ELIP was sevenfold greater than when
unencapsulated NO was administered, and this liposome
r e m a i n e da ne ﬀective delivery agent even in the presence of
NO-binding hemoglobin. Furthermore, NO-ELIPs triggered
a signiﬁcant reduction in hyperplasia, in contrast with Ar-
ELIPs [85].
Liposomes can be targeted to pathologic sites by conju-
gating antibodies and other ligands to the liposomes’ phos-
phatidylethanolamine head groups [84]. This strategy could,
for example, selectively target the drug to blood vessels,
permitting more NO generating and also its accumulate
in endothelial cells, promoting vasodilation. However, the
direct conjugation of antibodies to NO-ELIPs results inJournal of Drug Delivery 5
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Figure 3: Structure of a OSM-PCLA-PEG-PCLA-OSM hydrogel. Reprinted from Nguyen and Lee [77], with the permission of Copyright
and Licensing Manager, Wiley-VCH Verlag GmbH & Co.
greater than 90% loss of antibody immunoreactivity, mainly
due to the denaturation induced by the gas pressurization
and freeze-thawing procedures. To avoid this drawback, NO-
ELIPs and antibodies have been linked by biotin/avidin-
mediated coupling, providing a novel conjugation method
allowing site-speciﬁc NO delivery [86].
Another class of liposomes that can be successfully used
as nanocarriers is the thermosensitive liposomes, which may
be employed in the storage, delivery, and active release
of NO in a heat-mediated manner [87, 88]. Tai et al.
[89] encapsulated spermine NONOate (SPER/N2O2), a
zwitterionic diazeniumdiolate employed as an NO precur-
sor, in liposomes composed of phospholipids of diﬀerent
temperature sensitivities (Figure 4). Upon heating, an inﬂux
of extraliposomal protons decreased the intraliposomal pH,
diminishing the pH gradient across the membrane and
subsequently inducing rapid NO release. The collapse of
the pH gradient suggests that heat induced an increase
in the lipids bilayer’s permeability, allowing proton inﬂux.
SPER/N2O2 is known to spontaneously dissociate into two
molecules at a much faster rate at physiological pH than
at the basic pH, demonstrated by slower NO release from
basic intra-liposomal solution than from physiological intra-
liposomal solution. The degree of the slowed NO release was
also dependent on the speciﬁc phospholipid composition
of the liposomes. Moreover, the presence of a stronger pH
gradient when the liposomes were applied to a more acidic
environment increased proton inﬂux and thus NO release.
Because heat is generated in some pathological conditions,
such as in tumor tissue, thermo-sensitive liposomes contain-
ing NO may have applications in anticancer therapeutics [8].
Dinh et al. [90] investigated the eﬀect of the hydropho-
bic structure of liposomes’ phospholipids and surfactant
micelles on NO formation from zwitterionic diazenium-
diolates. The acid-catalyzed dissociation of NO has been
examined in phosphate-buﬀered solutions of sodium dode-
cyl sulfate (SDS) micelles and 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) and 1,2-dipalmitoyl-sn-glycero-3-
[phospho-(1-glycerol)] sodium salt (DDPG) phospholipid
liposomes. Both phosphatidylcholine and phosphatidylglyc-
erol liposomes catalyze NO dissociation from diazenium-
diolate substrates. The larger catalytic factors observed for
DPPGliposomes thanforDPPC liposomes and SDSmicelles
arise from the ability of the anionic liposome to concentrate
the reactants at the liposome surface. This is accomplished
through coulombic attraction of aqueous hydrogen ions and
positivenitrogencentersinthediazeniumdiolatezwitterions.
These ﬁndings provide insight into the interactions expected6 Journal of Drug Delivery
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with the permission of Elsevier.
between diazeniumdiolate substrates and the charged aque-
ous interfaces that they may encounter when employed as
NO donors in a biological environment.
Liposomes have also been used as models for bilayer
membranes in studies to explore the eﬀect of diﬀerent
phospholipids on diazeniumdiolate reactivity. It was found
that anionic liposomes increased the dissociation rate of
NO from diazeniumdiolate [91]. This study leads to a
better understanding of the local environmental factors
inﬂuencing NO donors’ reactivity, and, since negatively
charged phospholipids are important components of mem-
branes and pulmonary surfactants, it may help explain the
success obtained in experiments using diazeniumdiolate as
a pulmonary vasodilator [92]. In another study, it was
shown that positively charged liposomes, derived from
the synthetic surfactant DOTAP, increase the dissociation
of O2-arylated diazeniumdiolate prodrugs catalysed by
the enzyme glutathionetransferase, in a membrane model
system [91]. This prodrug has been successfully used to
target NO to acute myeloid leukemia cells on activation
by glutathione/glutathione S-transferase.[93–95]. A cationic
liposome composed of DOTAP has been used to transfer
the gene nitric oxide synthase (NOS) to vascular smooth
cells, which indicates the potential therapeutic relevance for
this transfer system to treat cardiovascular diseases [96].
These studies surely give insight into the use of charged
liposomes as a strategy to deliver NO in a site-speciﬁc way,
which would make them clinically more relevant. Cationic
liposomes could be used, for example, not only for gene
transfer, but to deliver a nitric oxide donor to blood vessels,
which could enable a more potent vasodilatation because of
theabilityofcationicliposomestointeractwithendothelium
cells via electrostatic interaction [97].
3.2. Solid Lipid Nanoparticles. Solid lipid nanoparticles,
composed of a lipid matrix stabilized by a surfactant, have
great potential as drug-delivery systems due to their safety,
high physical stability, and controlled release capability.
Additionally, lipid carriers may enable the successful topical
administration of many drugs due to attachment to the
skin surface, allowing lipid exchange between the outermost
layers of the carriers [98–100]. Solid lipid nanoparticles
(SLNs) were ﬁrst introduced in the early 1990s, followed
by the second-generation technology of nanostructured lipid
carriers(NLCs),particlesproducedusingablendofsolidand
liquid lipids to increase drug loading [101].
[Ru(Terpy)(bdqi)NO](PF6)3, an NO donor nitrosyl
ruthenium complex (NRC), has been bound to lipid carriersJournal of Drug Delivery 7
for topical administration. This system exhibited improved
stability in the skin and NO release by visible light irra-
diation, with potential applications in the treatment of
skin cancer [102]. NO was constantly released in an NRC
solution, in an SLN suspension and in an SLN solution
in contact with skin, while its encapsulation was preserved
when NRC-loaded SLNs were lyophilized. Additionally,
photochemical studies demonstrated that ultraviolet-visible
(UV-Vis) light irradiation triggered NO release from NRC-
loadedSLNsapproximatelytwofoldgreaterthanthatofNRC
in solution. This approach may be useful in improving NRC
reduction.
4.InorganicNanocarriers
4.1. Gold Nanoparticles. Gold nanoparticles (GNPs) and
goldmonolayer-protectedclusters(MPCs)provideattractive
delivery vehicles [103, 104] .T h eg o l dc o r ei si n e r ta n d
nontoxic, while the particles themselves are monodisperse
andsmallinsize(1.5–10nmindiameter)andpossessadense
gold core that allows imaging. Moreover, GNPs and MPCs
exhibit unique chemical and physical properties deﬁned by
the protecting ligands used during their synthesis and their
functional groups, such as thiols, phosphines, and amines,
whichexhibitanaﬃnityforgoldsurfaces[105].Forexample,
GNP solubility is governed by the structure of the protecting
ligand. The particles can be stabilized by a variety of thiol
ligands that are readily modiﬁed by bromo-, amino-, and
carboxy-terminated alkanethiols via place-exchange reac-
tions. Using these functional groups, it is possible to anchor
additional moieties, such as oligonucleotides, proteins and
antibodies, generating multifunctional delivery systems for
gene-based, antitumor, and antibacterial therapeutics [105].
Conventional methods of GNP synthesis consist of
the reduction of aqueous tetrachloroaurate (AuCl4
−)w i t h
sodium citrate or sodium borohydride [106, 107] and the
Brust-Schiﬀrin method of two-phase synthesis and stabiliza-
tionbythiols[108].Severalvariationsonthesemethodshave
also been implemented [109–111].
GNPs have been described as gene-delivery vehicles for
the controlled and directed transport of plasmid DNA,
siRNA or antisense oligonucleotides into living cells. Indeed,
GNPs have arisen as a more eﬀective alternative to viral
vehicles, which can present unpredictable cytotoxicity and
immune responses [103, 112]. GNPs functionalized with
ﬂuorescent ligands have been used to characterize interac-
tions and mechanisms during various applications. Zhang
et al. reported the ﬂuorescence quenching of CdSe NPs by
GNPs due to ﬂuorescence resonance energy transfer (FRET),
which can be utilized as a basis for ultrasensitive analytical
techniques in biology and medicine [107].
GNPs may represent a novel platform for the targeted
delivery of NO in vivo [113, 114]. GNPs functionalized
with carboxy-terminated alkanethiols have been synthesized
as a scaﬀold for NO-photoreleasing nanoparticles [31].
Meanwhile, Rothrock et al. reported the synthesis and
stability of N-diazeniumdiolate, NO-donor GNPs modiﬁed
with diﬀerent amine-derivatized monolayers. Because NO
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Figure 5: Nanocontainers for NO storage. Reprinted from Ghosh
et al. [116], with the permission of Elsevier.
is highly reactive and may disrupt gold-sulfur bonds,
they studied the stability of these GNPs after exposure
to high NO pressures. It was observed that NO release
from diazeniumdiolate-modiﬁed GNPs was also tunable by
varying the amine precursor structure, suggesting an NO
release/diazeniumdiolate structure relationship.
Further functionalization of GNPs with receptor
molecules, enabling speciﬁc antibody-antigen or ligand-
receptor interactions, may allow targeting to speciﬁc tissues
or cells [114]. Such targeted controlled release of NO
could be an eﬀective therapy for hypoxic respiratory failure
associated with pulmonary hypertension. Polizzi et al.
demonstrated that NO can be eﬃciently stored by covalent
linking to polyamine-stabilized GNPs via formation of acid
labile N-diazeniumdiolate [115]. Additionally, they showed
eﬀective NO release from the water-soluble nanocontainers
under acidic conditions (pH 3). pH-responsive materials
have applications in drug delivery due to the mild acidic
environment of inﬂamed tissues and tumors (pH ∼ 6.8) and
in such cellular vesicles as endosomes (pH ∼ 5.5–6.0) and
lysosomes (pH ∼ 4.5–5.0) (Figure 5)[ 116].
GNPs have been shown to catalyze NO generation when-
ever they come into contact with fresh blood serum. Mean-
while, NO has a relatively short lifetime in the blood due
to its reactivity with various blood components, including
hemoglobin. More abundant and stable forms of NO in the
bloodareS-nitrosoadductswiththiolgroups(RSNOs),such
as S-nitrosoalbumin (AlbSNO), S-nitrosocysteine (CysNO),
and S-nitrosoglutathione (GSNO) [117]. These compounds
may function as NO-carrying systems, prolonging the half-
life and spatial impact of NO.
NO plays an important role in the control of vascular
tone. It activates the soluble guanylyl-cyclase (sGC) and
G-kinase protein, which decreases the cytosolic calcium
concentration ([Ca2+]c) in the vascular smooth muscle
cells (VSMCs) [118, 119]. GNPs have been synthesized
and functionalized with nitrosyl ruthenium complex to
investigate if this system potentiates the NO release and
the vascular relaxation induced by the nitrosyl ruthenium
complex. This NO-release GNP system induced a dose-
dependent relaxation in endothelium denuded aortic rings
better than the complex only [120].
4.2. Silica Nanoparticles. The physiochemical properties,
stability and ability to form tunable porous structures with
tailored surface functionalities has led to the possibility8 Journal of Drug Delivery
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Figure 6: Schematic representation of the synthesis of N-diazeniumdiolate-modiﬁed SiNPs using TEOS and N-(6-
aminohexyl)aminopropyltrimethoxysilane as tetraalkoxysilane and aminoalkoxysilane precursors. Reprinted from Seabra and Dur´ an
[31], with the permission of Royal Society of Chemistry http://www.rsc.org.
of using of silica nanoparticles (SiNPs) in the controlled
delivery of drugs, biocides, genes, and proteins. Other
advantages to SiNPs is that they are nontoxic and that
their synthesis and isolation are straightforward [121]. SiNP
nanoconjugation with NO donors is also advantageous
[122], such as inorganic-organic hybrid SiNPs, functional-
ized ceramic materials prepared from silicon dioxide. The
surface of such particles can be modiﬁed with reactive
organic groups (amines, carboxylates, thiols, oleﬁns, halides,
and epoxides) capable of further functionalization using
deliverable molecules or via free silanol groups.
A new synthetic approach to preparing NO-releasing
SiNPs via a one-pot sol-gel process (Figure 6) includes
cocondensation of tetraethoxysilane (TEOS) or tetram-
ethoxysilane (TMOS) and aminoalkoxysilane with appropri-
ate amounts of ethanol or methanol, water and ammonia.
The amine functional groups within the SiNPs are subse-
quently converted into N-diazeniumdiolate NO donors via
exposure to high NO pressures (5atm) in the presence of
sodium methoxide (NaOMe) base [31].
Das et al. [123] developed a novel method of controlled
NO delivery to activated hepatic stellate cells (HSCs) in
an in vitro setting resembling chronic liver disease. Several
NO donors, such as S-nitroso-N-acetyl-DL-penicillamine
(SNAP), glyco-SNAP, 3-morpholino-sydnonimine (SIN-1)
and S-nitrosoglutathione (SNOG) were screened for long-
term, slow NO-releasing ability and chemical characteristics.
Au-SNAPs signiﬁcantly attenuated the proliferation and
vascular tube formation of the HSCs, an in vitro correlate
of angiogenic phenotype, by releasing NO. Thus, the unique
functionality of GNP- and SiNP-mediated drug-delivery sys-
tems may represent a new therapeutic approach to targeted
NO delivery in vivo [123].
Stevens et al. engineered NO-releasing SiNPs for NO
delivery to human ovarian cancer cells. They then compared
the cytotoxicity of the SiNPs coupled to various ratios of
an N-diazeniumdiolate in the presence of a small-molecule
NO donor [PYRRO/NO: sodium 1-(pyrrolidin-1-yl)diazen-
1-ium-1,2-diolate] to verify antitumor activity. This delivery
system allowed control of the therapeutic payload, visualiza-
tion of the nanoparticles via ﬂuorescent tags, and exertion of
NO-mediated anticancer eﬀects [124].
N-diazeniumdiolates also have been employed to elu-
cidate their potent eﬀects on diverse NO-mediated disease
states and pathophysiological disorders including cardio-
vascular disease and ischemia-reperfusion injury. However,
the use of these compounds is limited due to their low
solubility in physiological media, lack of speciﬁc targeting,
and low capability to deliver therapeutic concentrations of
NO, which decrease their potential clinical application. The
coupling of the N-diazeniumdiolates to the nanoparticles
delivery systems have been improved NO storage and release
capability. Shin and Schoenﬁsch reported a new synthetic
route to prepare NO-releasing silica particles through the
methodology that permit the development of NO storage
and delivery scaﬀolds for pharmacological applications
[121].
4.3. Quantum Dots. Nanotechnology can be exploited to
improvetheutilityofﬂuorescentmarkersusedfordiagnostic
purposes. Fluorescent nanocrystals, also known as quantum
dots (QDs), may potentially overcome the inherent disad-
vantages of other common ﬂuorescent markers, including
the requirement of color-matched lasers, the occurrence
of ﬂuorescence bleaching and the lack of discrimination
between multiple dyes. The bioimaging applications of QDs
include in vitro and in vivo imaging of live cells and in vivo
imaging of cancers and tumor vasculature [125, 126]. In vivo
imaging using QDs has also been reported for lymph node
mapping, blood pool imaging, and cell subtype isolation
(Figures 7(a)–7(c)). Additionally, Ballou and coworkers
[127] injected PEG-coated QDs into the mouse bloodstream
and investigated how the surface coating aﬀected circulation
lifetime (Figure 7)[ 128].
QDsareformedasacoreofsemiconductorclustersofII–
VI, III–V, and IV–VI column elements (as CdS, CdSe, CdTe,
InAs, and GaN) with diameters of several nanometers. This
core is usually covered by a surface-capping shell consisting
of a passivating material that should be of a wider bandgap,
or energy diﬀerence between the valence and conduction
bands, than the core material, ZnS [132–135]. The presence
of a shell dramatically increases the ﬂuorescence quantum
yields (QYs) of QDs nanocrystals by passivating surface
nonradiative recombination sites [136] and also reducesJournal of Drug Delivery 9
(a) (b)
(c) (d)
Figure 7: In vivo targeting and imaging using QDs. (a) Ex vivo tissue examination of QD-labeled cancer cells trapped in a mouse lung [129].
(b) Near-infrared ﬂuorescence of water-soluble type II QDs taken up by sentinel lymph nodes [130]. (c) In vivo simultaneous imaging of
multicolor QD-encoded microbeads injected into a live mouse [131]. (d) Molecular targeting and in vivo imaging of a prostate tumor in a
mouse using a QD-antibody conjugate (red) [131]. Reprinted from Gao et al. [128], with the permission of Elsevier.
leaching of damaging metal ions by oxidation from the
surface [134, 135].
Typically, QDs are synthesized in organic solvents and
exhibit hydrophobic surface ligands that could be replaced
by such water-soluble bifunctional molecules as peptides,
antibodiesornucleicacids[137–144].Forbiologicalapplica-
tions, the CdSe/ZnS core/shell composite is the best available
QD ﬂuorophore because its chemistry is the most reﬁned
[145].
QDs exhibit a broad absorption spectrum for single
excitation sources; a large molar absorption coeﬃcient that
increases toward the UV region; a narrow and symmetric
emission spectrum for multiple-color imaging (full width
at half maximum <30–40nm), a high-ﬂuorescence QY,
and superior photostability [146]. The onset of absorption
and the spectral position of the emission band (Figure 8)
can be easily tuned by controlling the particle size and
their material composition [132]. These unique optical and
electronic properties justify the increasing research into and
application of QDs in imaging of cellular cancer targets, in
vivo multiphoton ﬂuorescence for deep tissue visualization,
a n dF R E T -b a s e ds e n s i n g[ 134, 135, 147].
One of the most important emerging applications of
QDs is traceable drug delivery [148], which has the potential
to elucidate the pharmacokinetics and pharmacodynamics
of drug candidates and to provide design principles for
drug carrier engineering. For nanocarrier development and
optimization, QDs can serve as an excellent prototype from
which biocompatible carriers of similar sizes and surface
propertiescanbemadeforclinicaluses.Currentapplications
ofQDsindrugdeliveryarefocusedontwomajorareas:using
QDs as carriers and labeling therapeutics [149] or coupling
drug carriers with QDs [149, 150].
The investigation of luminescence nanoparticles as light
sources for cancer therapy is also very interesting. The
intense and stable emission ﬂuorescence, high QY, large
molar absorption coeﬃcient in a wide spectral range, and
the ability to transfer energy of QDs permit their use as
photosensitizers in photodynamic therapy (PDT). Recent
research has focused on developing photosensitizing QDs for
theproductionofradicalsuponabsorptionofvisiblelight.In
spite of the fact that visible light is safe, this approach is only
suitable for the treatment of superﬁcial tumors [151].
Cancer treatment requires high accuracy in delivering
ionizing radiation to reduce toxicity to surrounding tissues.
In the QD structure, multiple surface ligand sites provide
the opportunity to tether functional groups to the surface,
improving solubility properties and biological speciﬁcity
[152].10 Journal of Drug Delivery
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Figure8:Size-dependentopticaleﬀectsofsemiconductornanopar-
ticles. Semiconductor nanoparticles contain size-dependent elec-
tronic and optical properties. A series of ﬁve diﬀerent emission
spectra of sized ZnS-capped CdSe nanoparticles called QDs is
used to demonstrate this principle (colored dotted lines), in
juxtaposition with the absorption spectrum (solid black line).
The energy transfer between QDs and molecules in cells
(such as triplet oxygen (3O2)) can induce the generation
of reactive oxygen species (ROS) in the form of singlet
oxygen (1O2) and anion superoxide (O2
−), which promote
apoptosis [22]. Intracellular release of QDs can be facilitated
by functionalization, resulting in soluble, biocompatible
QDs. QDs linked to NO-donor molecules can speciﬁcally
lead to eﬀective treatment of large tumors by PDT [153].
In this case, the nitrosyl compounds can generate, under
light application, ROS and nitrogen (NOS) species via QD
excitation, enabling tumor cell death [22, 152].
Neuman et al. [152] demonstrated enhanced NO photo-
generation in trans-Cr(cyclam)(ONO)2+ (cyclam = 1,4,8,11-
tetraazacyclotetradecane) when conjugated to water-soluble
CdSe/ZnS core/shell QDs, indicating that the QDs may
sensitize photoreactions of this nitrite complex. Numerous
papers have related the use of nitrosyl or nitrite compounds
that release NO under visible light irradiation in PDT.
Furthermore, some of these compounds can also be applied
asvasodilators,deliveringNOinresponsetoreductorstimuli
[19, 153].
5.InnovationsandIntellectualProperty
The storage of NO and its controlled release from donors
is diﬃcult, partly due to the gaseous nature of NO and
its instability in the presence of oxygen. Therefore, eﬀective
NO delivery systems are highly desirable and potentially
lucrative, leading to the patenting of several inventions
that combine NO donors with nanotechnology. Liposomes,
capable of delivering one or more NO generators when
composed of dimyristoylphosphatidylcholine (DMPC) and
dimyristoyl-phosphatidylglycerol (DMPG) [154], wereintel-
lectually protected. Another invention described liposome
formation from lipids containing the S-nitroso moiety –S–
N]O, the O-nitroso moiety –O–N]O and/or an N-nitroso
moiety, including the NONOates, resulting in beneﬁcial
therapeutic eﬀects [155, 156].
NO-releasing nanomaterials have also been protected by
patents,includingsystemsbasedoncarbonnanotubes.These
nanomaterials contain NO or gases with NO-like biological
activity, with the gases noncovalently bound to a compound,
allowing both the storage and the controlled release of
NO gas. Compounds disclosed in the invention include
polymers, articles, pills, capsules, and medical devices [157].
Polymeric micelles for the delivery of NO have been
patented, such as micelles for N-diazeniumdiolate adminis-
tration [158]. Nano- and microparticulates for NO release
have also been legally protected. One such invention pro-
vides an oral therapeutic comprising at least one NO
donor coupled with an orally acceptable carrier [159].
Another patent describes the synthesis of biodegradable
and nonbiodegradable nanoparticles for coating medical
devices, such as intracoronary stents, in order to deliver
NO donors and other active drugs [160]. Nanoparticulate
systems containing a metallic cluster core (gold, platinum,
silver, magnetite, quantum dots, or a combination thereof),
a dendritic network core (polypropylenimine, polypeptide,
polyamidoamine, polyarilether, polyesther, polyamide, tri-
azine dendrimer, or dendritic polyglycerol), a cocondensed
silica network, or a combination thereof have also been
patented [161]. Finally, dendrimers for NO delivery are
protected by patent [162].
Despite considerable advances and numerous patents,
there are currently no commercially available nano- or
microcarriers for NO delivery.
6. Considerations
The clinical potential of NO-containing particles is signiﬁ-
cant, although several prerequisites are necessary, including
optimized delivery strategy, tissue targeting, and controlled
and sustained NO release. Current nanotechnology-based
systemsarehighlypromisingwithrespecttotheseproperties.
The extended circulation of particles with concomitant sys-
t e m i cd e l i v e r yo fN Oc o u l db eu s e dt ot r e a ts e v e r a ld i s o r d e r s
such as systemic infections and malignant hypertension.
Nanotechnologymayalsoproveusefulinthelocaldeliveryof
NO to treat peripheral vascular disease, chronic wounds, and
otherconditionsassociatedwithendothelialdysfunctionand
poor perfusion. Nanotechnology may also prove useful in
the local delivery of NO to treat peripheral vascular disease,
chronicwoundsandother.Nanocarriersofnitricoxidemake
the agent more available to the systemic circulation and
also can enhance a target of NO, the interaction of nitric
oxide with blood vessels, through of use of antibody moieties
to selectively target drug-delivery vehicles to blood vessels.
However, at present, there are many new NO-releasing
molecules but few eﬀective NO-releasing drugs.
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